A Phase 3 interventional study of Sotagliflozin and Placebo in Kidney Transplant Recipient, sponsored by University of British Columbia. Not yet recruiting at 25 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University of British Columbia · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will examine whether sotagliflozin, a medication that may protect the heart and kidneys, can improve long-term health in people who have received a kidney transplant. The study will compare sotagliflozin with an inactive placebo in approximately 900 adult kidney transplant recipients. Researchers will assess whether the medication can reduce the risk of kidney transplant failure, worsening kidney function, heart problems, stroke, heart attack, heart failure, and death. The study will also closely monitor participants for possible side effects, including infections, dehydration, fractures, and rejection of the transplanted kidney.
RENAISSANCE (Cardiovascular and Renal Protection with SGLT Inhibition in Kidney Transplant Recipients) is a pragmatic, prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sotagliflozin in adult kidney transplant recipients (KTRs).
Scientific Background and Rationale
Kidney transplant recipients remain at substantial risk of premature death, cardiovascular disease (CVD), heart failure (HF), and progressive loss of kidney transplant function. Cardiovascular complications are a leading cause of death among KTRs, while progressive deterioration in allograft function remains a major contributor to long-term transplant failure. These cardiovascular and kidney complications are interrelated, with deterioration in either organ system potentially contributing to dysfunction in the other.
Sodium-glucose cotransporter (SGLT) inhibitors have demonstrated cardiovascular and kidney protective effects in individuals with diabetes, heart failure, and chronic kidney disease (CKD), including reductions in cardiovascular events, hospitalization for heart failure, and progression of kidney disease. However, kidney transplant recipients have largely been excluded from previous large randomized clinical trials because of concerns regarding infection, volume depletion, and potential effects on transplant function and rejection. Although small randomized studies and observational data in KTRs suggest potential benefits and an acceptable safety profile, adequately powered randomized evidence is lacking.
RENAISSANCE is designed to address this evidence gap by evaluating whether sotagliflozin can improve long-term cardiovascular and kidney outcomes in KTRs while maintaining an acceptable safety profile.
Study Design and Intervention
Approximately 900 adult kidney transplant recipients will be randomized in a 1:1 ratio to receive either sotagliflozin 200 mg orally once daily or matching placebo. Study treatment will be administered in addition to participants' usual kidney transplant care, including maintenance immunosuppressive therapy and individualized management of cardiovascular risk factors.
Randomization will be stratified according to diabetes status and time since transplantation (less than 5 years versus 5 years or longer). The study will be double-blinded, with participants, investigators, study coordinators, and clinical site personnel unaware of treatment assignment. Active treatment and placebo tablets will be identical in appearance. Treatment allocation will be accessible only to designated unblinded pharmacy and coordinating center personnel, with emergency unblinding available when medically necessary.
Participants will receive study intervention for up to approximately 4.5 years, depending on enrollment timing, and will remain in the study until study closeout. Study medication will be discontinued approximately 4 weeks before the end of the study to allow assessment of kidney function following treatment withdrawal.
Participant Follow-up and Study Procedures
RENAISSANCE incorporates a pragmatic study design intended to minimize participant burden and facilitate participation across geographically diverse populations. Study visits may be conducted in person, by telephone, or through secure video communication, according to participant and investigator preference. Participants are not required to travel to their transplant center for study visits or laboratory testing.
Following randomization and initiation of study medication, participants will have an initial safety assessment approximately 2 to 6 weeks after starting treatment. This assessment includes evaluation of serum creatinine and estimated glomerular filtration rate (eGFR) to monitor kidney function following treatment initiation.
Subsequent study assessments will occur approximately every 3 months, with a 28-day visit window. Assessments will include review of medical history, concomitant medications, study medication adherence, adverse events, weight, and blood pressure. Serum creatinine and other clinically available laboratory results will be collected approximately every 3 months, while urine albumin-to-creatinine ratio will be assessed approximately every 6 months.
Whenever possible, laboratory results and clinical measurements obtained as part of routine transplant care will be used for study purposes to minimize additional testing. Participants may use their local laboratory and healthcare providers, with appropriate authorization for collection of clinical information. If required laboratory assessments are not available through routine care, study-related testing will be arranged.
At the end of the treatment period, kidney function will be assessed at study medication discontinuation and again approximately 4 weeks after discontinuation to evaluate changes following the treatment washout period.
Safety Monitoring and Risk Mitigation
The safety of sotagliflozin in kidney transplant recipients is a central component of the study. Particular attention will be given to potential adverse effects associated with SGLT inhibition, including genital mycotic infections, urinary tract infections, volume depletion, symptomatic hypotension, diabetic ketoacidosis, hypoglycemia, diarrhea, bone fractures, and changes in kidney function. The study will also monitor for acute kidney injury, infections requiring emergency care or hospitalization, kidney biopsy, and biopsy-proven acute transplant rejection.
Participants will receive counseling regarding potential risks and appropriate precautions during treatment. They will be instructed to temporarily hold study medication during periods of acute illness or fasting and during treatment of intercurrent urinary tract or genital yeast infections, in consultation with their healthcare provider and study investigator. Investigators may also coordinate adjustments to concomitant diuretics or glucose-lowering medications when clinically indicated to minimize the risk of volume depletion or hypoglycemia.
Study medication may be permanently discontinued when continued treatment is considered inappropriate for participant safety, including clinically significant adverse events, initiation of dialysis, kidney retransplantation, or pregnancy. Discontinuation of study medication does not automatically result in withdrawal from the study. Participants will be encouraged to continue study follow-up, allowing collection of clinical outcomes and safety information regardless of treatment discontinuation.
Outcome Assessment and Analysis
The study will evaluate the effects of sotagliflozin on major cardiovascular and kidney outcomes, including mortality, kidney transplant failure, cardiovascular events, heart failure events, and changes in kidney function over time. Clinical events, including cause of death, stroke, myocardial infarction, and heart failure events, will be reviewed by an independent adjudication committee blinded to treatment assignment.
The primary efficacy analysis will use a hierarchical composite approach that prioritizes clinically important outcomes, with all-cause mortality and kidney transplant loss ranked above cardiovascular events, sustained decline in kidney function, and heart failure events. Longitudinal kidney function will also be evaluated using eGFR trajectories over the treatment period. Additional analyses will assess cardiovascular and kidney outcomes, metabolic measures, albuminuria, and safety events.
The study will compare outcomes between the sotagliflozin and placebo groups to determine whether treatment provides cardiovascular and kidney protection without an unacceptable increase in adverse events.
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At increased risk for worsening allograft function or cardiovascular event as defined by one of the following groups:
Exclusion Criteria:
History of any other acute or chronic medical condition (e.g., urogenital abnormalities) or pre-planned surgical procedure that in the opinion of the investigator would compromise the safety of the patient or the integrity of the study results.
A woman of child-bearing potential is defined as a participant who has:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Sotagliflozin
Drug: Placebo
Sotagliflozin 200 mg PO OD will be administered for 3-4.5 years.
Also known as: LX4211
Matching placebo will be administered for 3-4.5 years.
Hierarchical Composite of All-Cause Mortality, Kidney Transplant Loss, Non-Fatal Stroke or Myocardial Infarction, Sustained 40% Decline in eGFR, Heart Failure Events, and Total eGFR Slope
A hierarchical composite endpoint consisting of the following components, ranked in order of clinical importance: 1. All-cause mortality. 2. Kidney transplant loss, defined as chronic dialysis for more than 90 days, retransplantation, or sustained eGFR ≤15 mL/min/1.73 m² for more than 3 months. 3. Non-fatal stroke or non-fatal myocardial infarction (MI). 4. Sustained 40% decline in estimated glomerular filtration rate (eGFR) from screening, confirmed by two creatinine measurements obtained at least 3 months apart. 5. Heart failure (HF) events, defined as hospitalization for HF or urgent treatment for HF. 6. Total eGFR slope, calculated using longitudinal eGFR measurements from screening to the last on-study drug visit and expressed in mL/min/1.73 m²/year. The hierarchical composite will compare treatment groups according to the prespecified ranking of these outcomes.
Time frame: From randomization to the end of the study (up to 4.5 years), with eGFR slope assessed from screening to the last on-study drug visit.
Number of Participants Experiencing Serious Adverse Events
Number of participants experiencing one or more serious adverse events (SAEs) during the study. Serious adverse events will be defined according to the applicable regulatory criteria for seriousness.
Time frame: From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing Adverse Events Leading to Permanent Study Drug Discontinuation
Number of participants who permanently discontinue the assigned study drug due to an adverse event.
Time frame: From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing Study Drug-Related Adverse Events
Number of participants experiencing at least one adverse event considered related to the study drug by the investigator.
Time frame: From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing Adverse Events of Special Interest
Number of participants experiencing at least one adverse event of special interest (AESI) during the study period. Adverse events of special interest include: * Genital mycotic infections * Urinary tract infections * Infectious complications requiring an emergency department visit or hospitalization * Amputations * Bone fractures * Diabetic ketoacidosis * Symptomatic hypotension * Symptomatic hypoglycemic episodes * Diarrhea * Kidney biopsy * Biopsy-proven acute rejection Each adverse event will be assessed and recorded throughout the study. Participants experiencing one or more adverse events of special interest will be counted in this outcome measure.
Time frame: From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing All-Cause Mortality
Number of participants who die from any cause during the study period.
Time frame: From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing Kidney Transplant Loss
Number of participants experiencing kidney transplant loss, defined as any of the following: * Requirement for chronic dialysis for more than 90 days. * Kidney retransplantation. * Sustained eGFR ≤15 mL/min/1.73 m² for more than 3 months.
Time frame: From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing Non-Fatal Stroke or Non-Fatal Myocardial Infarction
Number of participants experiencing a non-fatal stroke or non-fatal myocardial infarction during the study period.
Time frame: From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing a Sustained 40% Decline in eGFR
Number of participants experiencing a sustained decline of 40% or greater in estimated glomerular filtration rate (eGFR) from screening. The decline must be confirmed by two serum creatinine measurements obtained at least 3 months apart.
Time frame: From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing Heart Failure Hospitalization or Urgent Heart Failure Treatment
Number of participants experiencing a heart failure event, defined as hospitalization for heart failure or urgent treatment for heart failure.
Time frame: From randomization to the end of the study (up to 4.5 years).
Total eGFR Slope from Screening to the End of Study Drug Treatment
The total eGFR slope represents the rate of change in estimated glomerular filtration rate (eGFR), expressed in mL/min/1.73 m²/year. It will be calculated using longitudinal eGFR measurements obtained from screening to the end of study drug treatment.
Time frame: From randomization to the end of the study (up to 4.5 years).
Hierarchical Composite of Kidney Death, Kidney Transplant Loss, Sustained 40% Decline in eGFR, and Total eGFR Slope
A hierarchical composite kidney endpoint consisting of the following components: 1. Kidney death. 2. Chronic dialysis for more than 90 days. 3. Kidney retransplantation. 4. Sustained eGFR ≤15 mL/min/1.73 m² for more than 3 months. 5. Sustained 40% decline in eGFR from screening, confirmed by two serum creatinine measurements obtained at least 3 months apart. 6. Total eGFR slope, calculated using longitudinal eGFR measurements from screening to the end of study drug treatment and expressed in mL/min/1.73 m²/year. The components will be evaluated according to their prespecified hierarchical ranking.
Time frame: From randomization to the end of the study (up to 4.5 years); eGFR slope assessed from screening to the end of study drug treatment.
Hierarchical Composite of Cardiovascular Death, Non-Fatal Stroke, Non-Fatal Myocardial Infarction, and Heart Failure Events
A hierarchical composite cardiovascular endpoint consisting of the following components: 1. Cardiovascular death. 2. Non-fatal stroke. 3. Non-fatal myocardial infarction. 4. Heart failure events, defined as hospitalization for heart failure or urgent treatment for heart failure. The components will be evaluated according to their prespecified hierarchical ranking.
Time frame: From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing Cardiovascular Death
Number of participants who die due to cardiovascular causes during the study period.
Time frame: From randomization to the end of the study (up to 4.5 years).
Number of Participants Experiencing Kidney Death
Number of participants who die due to kidney-related causes during the study period.
Time frame: From randomization to the end of the study (up to 4.5 years).
Total eGFR Slope from Screening to the End of Study Drug Treatment
The total eGFR slope represents the rate of change in eGFR, expressed in mL/min/1.73 m²/year, calculated using longitudinal eGFR measurements from screening to the end of study drug treatment.
Time frame: From screening to the end of study drug treatment (up to 4.5 years).
Chronic eGFR Slope from 3 Months Post-Randomization to the End of Study Drug Treatment
The chronic eGFR slope represents the rate of change in eGFR, expressed in mL/min/1.73 m²/year, calculated using longitudinal eGFR measurements beginning 3 months after randomization and continuing to the end of study drug treatment.
Time frame: From 3 months post-randomization to the end of study drug treatment (up to 4.5 years).
Comprehensive eGFR Slope from Screening to the End of the Study Washout Period
The comprehensive eGFR slope represents the rate of change in eGFR, expressed in mL/min/1.73 m²/year, calculated using longitudinal eGFR measurements from screening through the end of the study washout period.
Time frame: From screening to the end of the study washout period (up to 4.5 years).
Number of Participants Developing New-Onset Diabetes
Number of participants without diabetes at baseline who develop new-onset diabetes during the study period.
Time frame: From randomization to the end of the study (up to 4.5 years).
Change from Baseline in Body Weight Over the Study Drug Treatment Period
Change in body weight, measured in kilograms, from baseline (pre-randomization) to the end of study drug treatment. Body weight will be measured at the scheduled study visits to assess changes over time.
Time frame: Baseline (pre-randomization) to the end of study drug treatment (up to 4.5 years).
Number of Participants Permanently Discontinuing Study Drug
Number of participants who permanently discontinue their assigned study drug before the planned end of study drug treatment.
Time frame: From randomization to the end of study drug treatment (up to 4.5 years).
Change from Baseline in Urine Albumin-to-Creatinine Ratio Over the Study Drug Treatment Period
Change in urine albumin-to-creatinine ratio (UACR) from baseline (pre-randomization) to the end of study drug treatment. UACR will be measured using urine albumin and creatinine concentrations and expressed in mg/g (or the units specified by the laboratory). Measurements at scheduled study visits will be used to assess the trajectory of UACR over time.
Time frame: Baseline (pre-randomization) to the end of study drug treatment (up to 4.5 years).
Number of Participants Experiencing Acute Kidney Injury
Number of participants experiencing at least one episode of acute kidney injury during the study period, according to the prespecified diagnostic criteria.
Time frame: From randomization to the end of the study (up to 4.5 years).
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2027; primary completion for Oct 2031, 54 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotagliflozin
University of British Columbia →